binding affinity News and Research

RSS

DNA nets effectively target the spike protein and detect COVID-19 virus at very low levels

Tiny nets woven from DNA strands can ensnare the spike protein of the virus that causes COVID-19, lighting up the virus for a fast-yet-sensitive diagnostic test – and also impeding the virus from infecting cells, opening a new possible route to antiviral treatment, according to a new study.

23 Sep 2022

Deep mutational scanning for SARS-CoV-2 Omicron BA.1 and BA.2 subvariants

Researchers performed deep mutational scanning for the SARS-CoV-2 Omicron variant of concern sub-VOC BA.1 and BA.2 receptor-binding domains.

22 Sep 2022

What is the efficacy of aerosol treatment for SARS-CoV-2 infection?

In a new study, researchers assessed the efficacy of the scFv76 antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lung damage.

21 Sep 2022

Molecular engineered low-cost highly effective RBD-based COVID vaccine

In a recent study posted to the bioRxiv* preprint server, an international team of researchers developed a second-generation severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding domain (RBD) antigen (RBD-J6) by molecular engineering with two additional amino acid (aa) substitutions (S383D and L518D mutations) in a hydrophobic cryptic RBD core epitope to enhance stability and expression against SARS-CoV-2 variants of concern (VOCs).

19 Sep 2022

Lab experiments add further evidence to the bradykinin storm theory of COVID-19’s viral pathogenesis

A new paper published in Nature Communications adds further evidence to the bradykinin storm theory of COVID-19's viral pathogenesis -; a theory that was posited two years ago by a team of researchers at the Department of Energy's Oak Ridge National Laboratory.

16 Sep 2022

SARS-CoV-2 N escape mutations do not affect rapid antigen testing

A new study maps the escape mutations found in various strains of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could cause them to escape neutralization by antibodies or detection by rapid antigen tests that rely on antibody binding for a positive result.

16 Sep 2022

Development of improved monoclonal antibodies against SARS-CoV-2

In a new study, researchers explored strategies for the development of effective monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

15 Sep 2022

What is the impact of COVID-19 treatments targeting intracellular Neu1?

In a new study, researchers assessed the impact of targeting intracellular Neu1 on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

14 Sep 2022

SARS-CoV-2 Omicron BA.4.6 resistant to many therapeutic monoclonal antibodies in clinical use

In a recent study posted to the bioRxiv* preprint server, researchers in Taiwan and the United States explore the resistance of a newly emergent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sub-variant BA.4.6 to the therapeutic monoclonal antibodies currently being used to treat coronavirus disease 2019 (COVID-19).

12 Sep 2022

Scientists observe how SARS-CoV-2 protein dismantles critical immunity pathway

Over the past two years, scientists have studied the SARS-CoV-2 virus in great detail, laying the foundation for developing COVID-19 vaccines and antiviral treatments.

9 Sep 2022

The use of AlphaFold2-enabled molecular docking simulations to predict protein-ligand interactions for antibiotic drug discovery

Researchers demonstrated that advances in modeling protein-ligand interactions using machine learning-based approaches are needed to exploit AlphaFold2 for antibiotic discovery better.

9 Sep 2022

A rapid and efficient method of identifying neutralizing nanobodies directed against SARS-CoV-2

A recent PLoS ONE study detected neutralizing nanobodies against SARS-CoV-2 from nanobody phage display libraries and via in vitro and ex vivo high-throughput screenings.

2 Sep 2022

Intranasally delivered neutralizing antibody protects against SARS-CoV-2 Omicron and Delta variants

The current study focused on the ability of this nmAb to neutralize Delta, Omicron, and other VOCs, as well as its efficacy when given by the intranasal route in an animal model.

1 Sep 2022

N501Y mutation and SARS-CoV-2 spike protein-angiotensin-converting enzyme-2 binding

In a new study, researchers assessed the effects of N501Y mutation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein on binding to angiotensin-converting enzyme-2 (ACE-2).

1 Sep 2022

The effects of amino acid substitutions on the affinity of the SARS-CoV-2 spike RBD to the human receptor hACE2

Researchers performed a structural bioinformatics analysis to evaluate the binding energy of the SARS-CoV-2 Omicron variants of concern spike protein receptor-binding domain to human angiotensin-converting enzyme 2 receptor compared to other VOCs.

30 Aug 2022

Researchers report the exceptional binding and neutralizing potency of an ACE2 decoy against SARS-CoV-2 variants

Researchers explored the activity of an ACE2 decoy against SARS-CoV-2 Omicron variant.

30 Aug 2022

Researchers report large molecular compounds and nanoscale nanozyme of two traditional Chinese medicines may inhibit COVID-19 signaling

Researchers investigated the potential anti-COVID-19 activity of traditional Chinese medicine.

25 Aug 2022